Damora Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, executive compensation, and auditor ratification, with all board recommendations approved by a strong quorum. Shareholders selected a one-year frequency for future compensation votes. Full voting results will be filed with the SEC.
-
Damora, formerly Galecto, is refocusing on mutant CALR therapies for ET and MF, with a lead antibody asset entering clinical trials this year and a strong financial position. Their differentiated approach targets both Type 1 and Type 2 mutations, aiming for best-in-class efficacy and convenience.
Fiscal Year 2025
-
The acquisition brings a robust pipeline of anti-mutant calreticulin therapies for myeloproliferative neoplasms, supported by $285 million in financing. Integration of complementary assets and leadership aims to accelerate clinical development, targeting a $5 billion-plus market opportunity.
-
A novel dual ENL-YEATS and FLT3 inhibitor, BRM-1420, shows strong preclinical efficacy and safety in AML models, targeting high-risk genetic subsets and menin inhibitor resistance. Clinical trials are planned for 2026, with initial focus on relapsed/refractory AML and future combination strategies prioritized.